Literature DB >> 10613493

Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia.

D J Holt1, M M Herman, T M Hyde, J E Kleinman, C M Sinton, D C German, L B Hersh, A M Graybiel, C B Saper.   

Abstract

Neurochemical and functional abnormalities of the striatum have been reported in schizophrenic brains, but the cellular substrates of these changes are not known. We hypothesized that schizophrenia may involve an abnormality in one of the key modulators of striatal output, the cholinergic interneuron. We measured the densities of cholinergic neurons in the striatum in schizophrenic and control brains in a blind analysis, using as a marker of this cell population immunoreactivity for choline acetyltransferase, the synthetic enzyme of acetylcholine. As an independent marker, we used immunoreactivity for calretinin, a protein which is co-localized with choline acetyltransferase in virtually all of the cholinergic interneurons of the striatum. A significant decrease in choline acetyltransferase-positive and calretinin-positive cell densities was found in the schizophrenic cases compared with controls in the striatum as a whole [for the choline acetyltransferase-positive cells: controls: 3.21 +/- 0.48 cells/mm2 (mean +/- S.D.), schizophrenics: 2.43 +/- 0.68 cells(mm2; P < 0.02]. The decrease was patchy in nature and most prominent in the ventral striatum (for the choline acetyltransferase-positive cells: controls: 3.47 +/- 0.59 cells/mm2, schizophrenics: 2.52 +/- 0.64 cells/ mm2; P < 0.005) which included the ventral caudate nucleus and nucleus accumbens region. Three of the schizophrenic cases with the lowest densities of cholinergic neurons had not been treated with neuroleptics for periods from more than a month to more than 20 years. A decrease in the number or function of the cholinergic interneurons of the striatum may disrupt activity in the ventral striatal-pallidal-thalamic-prefrontal cortex pathway and thereby contribute to abnormalities in function of the prefrontal cortex in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10613493     DOI: 10.1016/s0306-4522(99)00279-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  34 in total

Review 1.  Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.

Authors:  Richard S Jope; Myoung-Sun Roh
Journal:  Curr Drug Targets       Date:  2006-11       Impact factor: 3.465

2.  Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators.

Authors:  Changho Han; Arindam Chatterjee; Meredith J Noetzel; Joseph D Panarese; Emery Smith; Peter Chase; Peter Hodder; Colleen Niswender; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer
Journal:  Bioorg Med Chem Lett       Date:  2014-11-18       Impact factor: 2.823

3.  M1 muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons.

Authors:  Xiaohui Lv; Jonathan W Dickerson; Jerri M Rook; Craig W Lindsley; P Jeffrey Conn; Zixiu Xiang
Journal:  Neuropharmacology       Date:  2017-03-20       Impact factor: 5.250

4.  Targeted ablation of cholinergic interneurons in the dorsolateral striatum produces behavioral manifestations of Tourette syndrome.

Authors:  Meiyu Xu; Andrew Kobets; Jung-Chieh Du; Jessica Lennington; Lina Li; Mounira Banasr; Ronald S Duman; Flora M Vaccarino; Ralph J DiLeone; Christopher Pittenger
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-05       Impact factor: 11.205

Review 5.  Psychiatric brain banking: three perspectives on current trends and future directions.

Authors:  Amy Deep-Soboslay; Francine M Benes; Vahram Haroutunian; Justin K Ellis; Joel E Kleinman; Thomas M Hyde
Journal:  Biol Psychiatry       Date:  2010-07-31       Impact factor: 13.382

Review 6.  Basal ganglia pathology in schizophrenia: dopamine connections and anomalies.

Authors:  Emma Perez-Costas; Miguel Melendez-Ferro; Rosalinda C Roberts
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

7.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

8.  Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia.

Authors:  Jessica A Wojtalik; Shaun M Eack; Bruce G Pollock; Matcheri S Keshavan
Journal:  Psychiatry Res       Date:  2012-11-15       Impact factor: 3.222

9.  Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome.

Authors:  Yuko Kataoka; Paul S A Kalanithi; Heidi Grantz; Michael L Schwartz; Clifford Saper; James F Leckman; Flora M Vaccarino
Journal:  J Comp Neurol       Date:  2010-02-01       Impact factor: 3.215

10.  Neuregulin 1 and susceptibility to schizophrenia.

Authors:  Hreinn Stefansson; Engilbert Sigurdsson; Valgerdur Steinthorsdottir; Soley Bjornsdottir; Thordur Sigmundsson; Shyamali Ghosh; Jon Brynjolfsson; Steinunn Gunnarsdottir; Omar Ivarsson; Thomas T Chou; Omar Hjaltason; Birgitta Birgisdottir; Helgi Jonsson; Vala G Gudnadottir; Elsa Gudmundsdottir; Asgeir Bjornsson; Brynjolfur Ingvarsson; Andres Ingason; Sigmundur Sigfusson; Hronn Hardardottir; Richard P Harvey; Donna Lai; Mingdong Zhou; Daniela Brunner; Vincent Mutel; Acuna Gonzalo; Greg Lemke; Jesus Sainz; Gardar Johannesson; Thorkell Andresson; Daniel Gudbjartsson; Andrei Manolescu; Michael L Frigge; Mark E Gurney; Augustine Kong; Jeffrey R Gulcher; Hannes Petursson; Kari Stefansson
Journal:  Am J Hum Genet       Date:  2002-07-23       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.